<DOC>
	<DOCNO>NCT00226759</DOCNO>
	<brief_summary>The anterior cruciate ligament ( ACL ) important stabilizer knee . Orthopedic surgeon replace torn ligament ACL reconstruction surgery . Surgical trauma initiate acute inflammatory response , include swell pain , lead restrict joint motion loss function . OMS103HP design deliver target therapeutic agent directly surgical site arthroscopic procedure inhibit inflammation pain begin . The purpose study assess effectiveness safety OMS103HP improve knee function follow ACL reconstruction . Secondary benefit evaluate include reduce postoperative pain , improvement knee range motion earlier return work .</brief_summary>
	<brief_title>Efficacy Safety OMS103HP Patients Undergoing Allograft Anterior Cruciate Ligament ( ACL ) Reconstruction</brief_title>
	<detailed_description />
	<mesh_term>Knee Injuries</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>15 65 year age In good general health ACL tear occur 2 week 18 month prior day arthroscopic surgery Undergoing primary unilateral ACL reconstruction use allograft ( patellar tendon bone , Achilles tendon , tibialis tendon , hamstring ) Able participate study rehabilitation protocol inclusion criterion No allergy individual ingredient OMS103HP No medication activity active ingredient OMS103HP define time interval prior surgery No associate knee injury likely interfere evaluation study drug exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Anterior cruciate ligament reconstruction</keyword>
	<keyword>ACL reconstruction</keyword>
</DOC>